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In 12 healthy, adult males, the epidermal content of 
both cAMP and cGMP was determined radioimmuno-
logically every 6 h over a period of 30 h, avoiding any 
ischemia, which can alter unphysiologically the in vivo 
levels of epidermal cyclic nucleotides. For cAMP a diur-
nal fluctuation with maximal level at midnight could be 
proved (p < 0.05), whereas cGMP, in contrast to exper-
iments in mice, revealed no significant variation during 
the test period. The presented results describe for the 
first time the diurnal course of human epidermal cG MP. 
Diurnal variations of epidermal mitotic activity and metab-
olism are wel l establis hed in animals (cf. [1) for review) [2). 
For human epidermis, resu lts concerning on ly the diurnal var-
iations of mitotic index and DNA-synthesis activity are avai l-
able [3-5). Diurnal variations of cycl ic nucleotides (cyclic aden-
osine 3',5'-monop hosphate, cAMP; cyclic guanosine 3',5'-
monophosphate, cGMP) essentially involved in epidermal pro-
liferation , differentiation, and metabolism [6] were experimen-
tally proved in mice on ly [7,8]. Except for our previous results 
[9], there is no information in the literature concern ing diurnal 
variations of cAMP in human epidermis. No investigations 
regarding diurnal variations of human epidermal cGMP have 
been performed. 
W ith respect to "ischemia" [10,11], our results must be 
co ns idered preliminarily, because the local anesthetics used in 
our previous study for biopsy sampling can influence the in 
vivo levels of cyc lic nucleotides due to t he "isc hemic effect." 
Thus, we reinvestigated our previous findin gs in a new study 
with a greater number of vo lu nteers a nd included ep idermal 
cGMP under improved test conditions. 
MATERIALS AND METHODS 
All chemicals used were of the highest purity available. Perchloric 
acid and potassium carbonate were provided by Merck, Darmstadt, 
F.R.G., and ["HJ cAMP and [' H] cGMP by New England Nuclear, 
Dreieich, F .R.G.; assay kits for the determination of cAMP and cGMP 
were purchased from The Radiochemica l Center Amersham Ltd., 
Braunschweig, F.R.G. 
The tests were performed on 12 male, healthy medica l students (age 
range, 23-29 years). Informed consent was obtained. Standardized test 
conditions were achieved by hospita lizing the volunteers during the 
study. Resting ti me was from 2200- 0600 h. Over a period of 30 h, every 
6th h start ing at 1200 h, 2 biopsies- one for cAMP, the other for 
cGMP determination - were done alte rnat ing t he right and left glu tea l 
region (12 biopsies per volunteer). At the same time venous blood 
samples were taken in prechilled EDTA tubes for measuring cAMP 
and cGMP in plasma (data not shown) . For biopsy sampling we 
combined and modified two previously published methods [ 10,12]: A 
th in strip of metal ( 150 X 40 X 0.3 mm) with a 10 nun-diameter hole 
was pressed on the sk in. The skin vau lted up through the hole. The 
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projecting skin was deep-frozen by bringing it into contact with a 
metallic, cylindrica l, flat -bottomed vessel (outer diameter 8 mm , length 
20 em) tilled with liquid nitrog-en. Fill ing was accomplished through 2 
circles of 5 small holes 5 em and 10 em from the bottom of the cylinder. 
For easier handling, a wooden stick had been fitted to the upper end of 
the vessel. The specimen was removed by cutting with a razor blade 
inserted between the metal strip and t he cylinder. The biopsies had an 
average diameter of .5 mm. Thus, the samples remained frozen. Possible 
thawing was avoided by repeated contact with the cyli nder. After 
weighing, the biopsies were wrapped in marked aluminum foi l and 
stored in liquid nitrogen until further processing. Subsequently the 
specimen was placed in a glass homogenizer (volume 2 ml; Braun 
Melsungen, F.R.G .) and homogenized under liquid nitrogen with a 
Teflon pestle (2000 rpm). Oeproteinization was performed by addjng 
0.5 ml 1 N perchloric ac id under ice cooling. After neutralization with 
an equivalent volu me 5 M J< 2C0:1, samples were centrifuged at 4000 g 
at 4•c for 10 min and washed twice with 0.5 ml ethanol. The combi ned 
supernatants were evaporated in a vacuum desiccator over anhydrous 
CaCb, resolved in 0.05 M Tris-buffer, pH 7.5, containing 4 mM EDTA, 
recentrifuged, and analyzed radioimmunologically. All samples were 
run in duplicate. A chromatographic precleaning was not necessary 
because of t he high specificity of the assays used. The cross-reactivity 
of the cA MP assay with cGMP was 0.8%, the corresponding value for 
the cGMP assay with cAMP was 0.0007%. In the residue, protein was 
measured accordi ng to the method of Lowry eta! [13]. The variation 
coefficient was 12.7% for cAMP and 8.7% for cGMP (n = 7). Recovery, 
determined with tritiated cyclic nucleotides, was 90% for cAMP and 
75 % for cGMP. The epidermal share (-70%) of the biopsies was 
evaluated after hematoxylin/eos in staining in a prestudy in 5 volun-
teers. 
Epidermal cyclic nucleotide levels were expressed by concentration 
per protein content as well as by concentration per wet weight. (data 
not shown). 
For statistical analysis , a distribution-free procedure (H-t.est) was 
used, because all data showed a markedly skew distribution. 
RESULTS 
Fig 1 a nd Table I (cAMP) and Fig 2 and Table II (cGMP) 
reveal t he epidermal nucleotide co ntent of t he 144 processed 
biopsies a nd t he diurnal course of both nucleotides at each test 
point over the 30-h test period. These figures and tables dem -
onstra te a 10-fold higher test period mean for cAMP (1.51 
pmol/ mg protein) compa red to cG MP (0.153 pmol/ mg prote in). 
For cAMP, midnight values excepted, t he individual data do 
not differ sign ifica ntly at a ny test point. They cumulate s ligh t ly 
below the test period mean. At midnight, however, the cAMP 
va lues ex hibit a widely scattered pattern , but their prevailing 
majority is s ituated a bove the test period mean. The difference 
between midnight values a nd a ll other data could be proved to 
be statistically s ignifican t ( p < 0.05). In Fig 2 a f1uctuation of 
cGMP levels ca n be seen zigzaggi ng a round t he test period 
mean. However, in con t rast to cAMP, t here is no prominent 
test point in t he data pattern actually differing in shape and 
magnitude from the others; t his was confirmed by statistica l 
ca lculations. 
DISCUSSION 
Numerous studies have been published concerning the epi-
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FIG 1. Diurnal variation in human epidermal cAMP. Single values 
(e) of epidermal cAMP in 12 healthy, equal aged males determined in 
a 30-h period. Mean values of cAMP (solid line) and 30-h mean (dotted 
line ) are delineated. Mean values ± SEM (pmoljmg protein) at each 
test point are (from left to right): 0.72 ± 0.08, 1.11 ± 0.33, 4.71 ± 0.92, 
1.11 ± 0.32, 0.64 ± 0.18, 0.79 ± 0.23. 
TABLE I. Epidermal cAMP content in I 2 males (TP I - 12) ouer 30 
hours 
Sampling time 
1200 1800 2400 0600 1200 1800 
TP 1 0.32 0.89 2.89 2.35 0.85 0.41 
TP2 0.52 0.62 9.77 0.40 0.72 0.63 
TP 3 0.74 4.58 0.83 0.50 0.66 0.55 
TP4 0.97 1.51 10.16 0.91 0.91 1.08 
TP 5 1.00 0.89 1.73 4.44 0.79 1.14 
TP6 1.10 1.30 2.13 0.75 0.65 1.12 
TP 7 0.64 0.95 7.08 0.63 0.25 0.83 
TP8 0.41 0.20 4.37 0.30 0.35 0.78 
TP9 0.91 0.47 5.05 0.66 0.52 0.73 
TP 10 0.39 0.41 6.35 0.81 0.67 0.47 
TP 11 0.75 0.93 3.72 0.58 0.49 0.65 
TP 12 0.83 0.55 8.57 1.00 0.87 1.05 
M 0.75 0.89 5.22 0.71 0.67 0.76 
X 0.72 1.11 4.71 1.11 0.64 0.79 
SEM 0.08 0.33 0.92 0.32 0.18 0.23 
Cycl ic AMP levels are expressed as pmolfmg protein. M represents 
the median , X the mean value, SEM the standard error of the mean. 
nucleotides (cf. [6,14] for review) . Diurnal variations of epider-
mal cAMP and cGMP have been studied in mice only [7,8]. 
Marks and Grimm [7] established a pronounced diurnal oscil-
la t ion of epidermal cAMP. They kept their animals under an 
artificial rhythm of light and dark periods, with light from 1800 
h to 0600 h and dark from 0600 h to 1800 h. cAMP fluctuations 
reached maximal levels at midnight, i.e. , in the experiment of 
Marks and Grimm the resting phase of the animals (mice are 
dark-active). Minimal levels of cAMP were reached during the 
active phase, which is the dark period in the artificial rhythm. 
Garte and Belman [8] also investigated mouse epidermal cGMP 
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with respect to diurnal variations. They kept t heir animals also 
under an artificial light- dark rhythm with light from 0600 h to 
1800 h, which coincides with natural condit ions. Maximal levels 
for cAMP were found at 0600 h; cGMP reached its maximum 
at 1000 h. Minimal levels for both cyclic nucleotides were 
situated at 2200 h and 1400 h, respectively. Corresponding with 
the study of Marks and Grimm, Garte and Belmann found 
epidermal cAMP to be maximal in the light period, which is 
the resting phase for the animals. 
Looking at our data, which reveal a statistically significant 
maximal level of cAMP at midnight, which for humans-"day-
active beings" is in their resting phase- our results are in 
agreement with the findings in mice. For the magnitude of 
epidermal cAMP the activity and resting periods, not actual 
clock time, seem to be important. The wide range of individual 
cAMP values at midnight cannot be exp lained; cGMP does not 
show this characteristic. Possibly, the individual levels of 
cAMP are more sensitive to diurnal variations. A direct com-
parison of our cyclic nucleotide values with those of Carte and 
Belman [8] and Marks and Grimm [7] is only restrictively 
possible because they refer their data to DNA content, but the 
level of our test period mean is in good accordance with other 
single point measurements [10,11] . In contrast to Garte and 
Belman we failed to demonstrate a clear minimum for cAMP 
because the results of all other test points, midn ight measure-
ments excluded, did not differ statistically significantly from 
each other. But in the present study we could confirm our 
previous results [9] showing the midnight cAMP maximum. 
The main difference between our results and those of Carte 
and Belman is that we could not prove s ignificant diurnal 
fluctuations for epidermal cGMP. There is only an "up and 
down" zigzagging uninfluenced by activity and resting phases 
around the test period mean. As in mice, human epidermal 
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FIG 2. Diurnal variation in human epidermal cGMP. Single values 
(e) of epidermal cGMP in 12 healthy, equal aged males measured every 
6th h over a period of 30 h. The dotted line represents the test period 
mean, whereas the solid line is the mean value at each test point. Mean 
values ± SEM (fmol/mg protein) are (from left to right): 167.20 ± 
23.71, 125.39 ± 7.45, 167.94 ± 17.82, 139.61 ± 15.19, 192.07 ± 17.87, 
127.86 ± 7.94. 
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TABLE II. Epidermal cGMP content in 12 males (TP 1- 12) over 30 hou.rs 
Sampling Lime 
1200 1800 24 00 0600 1200 1800 
TP 1 117.79 162.96 163.11 119.08 97.84 99.01 
TP 2 103.88 103.22 119.71 135.63 305.88 124.60 
TP 3 197.65 166.37 137.14 215.15 291.76 147.02 
TP4 251.61 120.83 232.97 176.58 202.53 179.66 
TP 5 151.90 131.39 308.33 89.70 164.71 112.00 
TP 6 152.54 118.81 141.94 94.62 159.22 155.56 
TP 7 139.68 142.85 115.03 128.57 248.00 117 .50 
TP8 103.78 153.33 195.45 111.71 146.09 85.71 
TP9 90.11 91.95 89.79 118.52 176.84 106.19 
TP 10 386.07 101.78 222.64 263.06 168.42 155.56 
TP 11 142.63 112.67 132.82 100.21 143.65 113.85 
TP 12 168.75 98.54 156.35 122.53 200.10 137.60 
M 147.27 119.82 149. 15 120.81 172.63 121.05 
X 167.20 125.39 167.94 139.61 192.07 127.86 
SEM 23.71 7.45 17.82 15.19 17.87 7.94 
Cyclic GMP levels are expressed as fmol/mg protein. Other details are as in Table l. 
The lack of diurnal variations of cGMP is t he crucial point 
of our study . Some hints, which might give a possible even 
though specu lative explanation about the ro le and influence of 
cGMP, a re presented by Dinnenda hl [15]: (1) Highest cGMP 
co ncentrations are found in a r thropods and other phylogenet-
ically older species. (2) In evolut ion a ry older areas of the brain 
e.g., cerebellum, t he cGMP content is much higher t ha n in t he 
cortex. The same occurs wit h the guanylate cyclase activity. (3) 
Acetylcholine, which causes a cGMP increase in a ll t issues with 
muscarinic receptors investigated to d ate, is a more primitive 
transmitter substance t han noradrenaline, the ,6-adrenergic 
effect of which is transmitted by adenylate cyclase stimulation. 
Thus, t he cGMP system might be a n atavism, which during 
evo lut ion lost its importance for cellular metabolism a nd pro-
liferat ion in favor of t he cAMP system. Alterations in cGMP 
con te nt m ay be only concomitant symptoms but not mediating 
links, like cAMP, in a biologic chain of information. Also for 
human epidermal proliferation which reaches maxima l levels 
in t he late evening or ea rly morn ing hours (cf. [1 ,3] for review) 
a nd m etabolism, th e newest concepts tend to neglect t he influ-
ence of cGMP a nd to favor cAMP [6) . The diurnal variation of 
hu man ep iderma l cAMP and its absence for cGMP support 
t hese concepts. 
We thank Miss I. Passier and Mr. E. Tomek for excellent technical 
ass istance. 
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